Evidence map›Paper›PMID 38589418›Full record

ArticleScientific reports2024

Inferring molecular inhibition potency with AlphaFold predicted structures.

Pedro F Oliveira, Rita C Guedes, Andre O Falcao

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Pedro F OliveiraLasige, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal.
Rita C GuedesResearch Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.
Andre O FalcaoDepartamento de Informática, Faculdade de Ciências, Universidade de Lisboa, 1749-016, Lisboa, Portugal. aofalcao@fc.ul.pt.

Funding

Fundação para a Ciência e a Tecnologia EXPL/QUI-OUT/1288/2021
6 · The paper itself

Abstract

Even though in silico drug ligand-based methods have been successful in predicting interactions with known target proteins, they struggle with new, unassessed targets. To address this challenge, we propose an approach that integrates structural data from AlphaFold 2 predicted protein structures into machine learning models. Our method extracts 3D structural protein fingerprints and combines them with ligand structural data to train a single machine learning model. This model captures the relationship between ligand properties and the unique structural features of various target proteins, enabling predictions for never before tested molecules and protein targets. To assess our model, we used a dataset of 144 Human G-protein Coupled Receptors (GPCRs) with over 140,000 measured inhibition constants (K

Indexed as

Machine LearningReceptors, G-Protein-CoupledHumansLigandsLigandsReceptors, G-Protein-CoupledIn silico drug discoveryMachine learningProtein structureProteo-chemometricsQuantitative structure-activity relationship modeling (QSAR)Structure based virtual screening

Identifiers

PMID38589418
PMCPMC11001998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.